---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-090182"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2026-08-14T20:35:17+00:00"
generated_at: "2026-08-14T20:41:34.250368+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology Q3 FY2026 revenue $1.5M, LYMPHIR demand accelerates

## Summary
- Revenue $1.5M for Q3 ended June 30, 2026 (vs $0 prior year); $7.1M for nine months.
- Net loss $8.9M ($0.08/share) for Q3; $41.1M ($0.42/share) for nine months, incl. $19.7M one-time CMO cancellation charge.
- Institutional vial orders grew 31% sequentially to 926 in Q3; July orders 383 vials, largest month; 44 institutions ordering.
- Cash $16.6M; received $9.7M from warrant exercises and $10M from first tranche of $25M senior secured term loan.
- Appointed Jonathan Peri as independent director; commercial team expanded to 29 professionals.

## SEC filing metadata
- accession: 0001213900-26-090182
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2026-08-14T20:35:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390026090182/0001213900-26-090182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390026090182/ea0302226-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-090182
- JSON: https://secwatch.observer/filing/0001213900-26-090182.json
- Plain text: https://secwatch.observer/filing/0001213900-26-090182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.